相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors
Ryan J. Sullivan et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
Gry Irene Magnussen et al.
BMC CANCER (2015)
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Yan Liu et al.
CLINICAL CANCER RESEARCH (2015)
Cell cycle control as a promising target in melanoma
Belinda Lee et al.
CURRENT OPINION IN ONCOLOGY (2015)
Will Targeting Chk1 Have a Role in the Future of Cancer Therapy?
Nandini Sakurikar et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
Khanh Do et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
Christian Posch et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Letizia Porcelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
Manali S. Phadke et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Aurora Kinase inhibitors: Current Status and Outlook
Vassilios Bavetsias et al.
FRONTIERS IN ONCOLOGY (2015)
Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
Anna E. Vilgelm et al.
CANCER RESEARCH (2015)
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Klaus G. Griewank et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Vipin Yadav et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J. Young et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
Ruth Thompson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Katherine L. Nathanson et al.
CLINICAL CANCER RESEARCH (2013)
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard et al.
CLINICAL CANCER RESEARCH (2013)
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-?B impairs this drug-induced senescence
Yan Liu et al.
EMBO MOLECULAR MEDICINE (2013)
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
John J. Nemunaitis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response
H. Christian Reinhardt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines
Lifang Xie et al.
MELANOMA RESEARCH (2013)
A potent Chkl inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
K. Brooks et al.
ONCOGENE (2013)
p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes
Carina Fung et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
A. Kathleen McClendon et al.
CELL CYCLE (2012)
Combined inhibition of Chk1 and Wee1 In vitro synergistic effect translates to tumor growth inhibition in vivo
Laura Carrassa et al.
CELL CYCLE (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
Edina Komlodi-Pasztor et al.
CLINICAL CANCER RESEARCH (2012)
Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells
Caroline Bonet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Patrick J. Roberts et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts.
C. Sanchez-Martinez et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong et al.
NATURE MEDICINE (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy
Gry Irene Magnussen et al.
PLOS ONE (2012)
Mitosis-targeted anti-cancer therapies: where they stand
K-S Chan et al.
CELL DEATH & DISEASE (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Kurtis D. Davies et al.
CANCER BIOLOGY & THERAPY (2011)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Checkpoint kinase inhibitors: a patent review (2009-2010)
Michael Lainchbury et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau et al.
EUROPEAN JOURNAL OF CANCER (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors
Rooshdiya Z. Karim et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2009)
The decision to enter mitosis: feedback and redundancy in the mitotic entry network
Arne Lindqvist et al.
JOURNAL OF CELL BIOLOGY (2009)
Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma Cells
Travis L. Schmit et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma
Amira Sanki et al.
PATHOLOGY (2007)
Cdk1 is sufficient to drive the mammalian cell cycle
David Santamaria et al.
NATURE (2007)
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R. Jackson et al.
NATURE REVIEWS CANCER (2007)
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
Alisa M. Goldstein et al.
JOURNAL OF MEDICAL GENETICS (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Roles of aurora kinases in mitosis and tumorigenesis
Jingyan Fu et al.
MOLECULAR CANCER RESEARCH (2007)
Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)
Raymond P. Perez et al.
CLINICAL CANCER RESEARCH (2006)
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Lyubomir T. Vassilev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Population-based prevalence of CDKN2A mutations in Utah melanoma families
Mark J. Eliason et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
S Burdette-Radoux et al.
INVESTIGATIONAL NEW DRUGS (2004)
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
K Vermeulen et al.
CELL PROLIFERATION (2003)
Cyclin dependent kinases and cell cycle control
PM Nurse
BIOSCIENCE REPORTS (2002)
Protein synthesis, proteolysis, and cell cycle transitions
T Hunt
BIOSCIENCE REPORTS (2002)
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
L Kneisel et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2002)
分享论文
